Art. -Nr.: HY-14674

CP-724714

Name: CP-724714
Brand: MedChemExpress
SKU: HY-14674
Price: 108.00 USD
Availability: InStock
Rating: 5 (4 reviews)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

CP-724714 is an orally active and selective HER2 tyrosine kinase inhibitor with an IC₅₀ of 10 nM. CP-724714 inhibits HER2 receptor autophosphorylation and blocks the downstream Ras-Raf-Mek-Erk signaling pathway, thereby inducing cell cycle arrest and apoptosis in tumor cells. CP-724714 exhibits antiviral activity and inhibits various porcine diarrheal coronaviruses, including SADS-CoV (IC₅₀ of 0.91 μM). CP-724714 is an inhibitor of the hepatic transport receptors OATP1B1/MDR1/BSEP, and can enter hepatocytes via active uptake and trigger the accumulation of drugs and bile acids within hepatocytes. CP-724714 can be used in research related to HER2-overexpressing breast cancer and porcine diarrheal coronavirus infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.72%
CAS. Nr.: 383432-38-0
Formel: C₂₇H₂₇N₅O₃
Molecular Weight:469.55

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CP-724714 Chemical Structure

CAS. Nr.: 383432-38-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

HER2

10 nM (IC₅₀)

ERK1

ERK2

RAF

Alle EGFR Isoform-spezifische Produkte anzeigen :

Alle Raf Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BT-20	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human BT-20 cells assessed as inhibition of cell growth Antiproliferative activity against human BT-20 cells assessed as inhibition of cell growth	[PMID: 17942920]
BT-474	EC₅₀	0.77 μg/mL Compound: Chemical Probe: CP-724,714	Antitumor activity against human BT-474-erbB2 cells xenografted bearing female athymic nu-nu CD-1 mouse assessed as reduction in tumor erbB2 receptor phosphorylation, po administration by ELISA method Antitumor activity against human BT-474-erbB2 cells xenografted bearing female athymic nu-nu CD-1 mouse assessed as reduction in tumor erbB2 receptor phosphorylation, po administration by ELISA method	[PMID: 17942920]
BT-474	IC₅₀	0.25 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth	[PMID: 17942920]
CAMA-1	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human CAMA-1 cells assessed as inhibition of cell growth Antiproliferative activity against human CAMA-1 cells assessed as inhibition of cell growth	[PMID: 17942920]
EFM-19	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human EFM-19 cells assessed as inhibition of cell growth Antiproliferative activity against human EFM-19 cells assessed as inhibition of cell growth	[PMID: 17942920]
HCC1419	IC₅₀	1 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human HCC1419 cells assessed as inhibition of cell growth Antiproliferative activity against human HCC1419 cells assessed as inhibition of cell growth	[PMID: 17942920]
MCF7	IC₅₀	9.8 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 17942920]
MDA-MB-157	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell growth	[PMID: 17942920]
MDA-MB-175-VII	IC₅₀	0.81 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MDA-MB-175-VII cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-175-VII cells assessed as inhibition of cell growth	[PMID: 17942920]
MDA-MB-361	IC₅₀	3.7 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MDA-MB-361 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-361 cells assessed as inhibition of cell growth	[PMID: 17942920]
MDA-MB-453	IC₅₀	2.5 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth	[PMID: 17942920]
MDA-MB-468	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth	[PMID: 17942920]
Sf9	IC₅₀	10 nM Compound: 37; CP-724714	Inhibition of recombinant GST-tagged HER2 (unknown origin) (catalytic domain 675 to 1225) residues expressed in baculovirus-infected Sf9 cells assessed as reduction of phosphorylation of polyglutamic acid/tyrosine incubated for 25 mins by spectrometery Inhibition of recombinant GST-tagged HER2 (unknown origin) (catalytic domain 675 to 1225) residues expressed in baculovirus-infected Sf9 cells assessed as reduction of phosphorylation of polyglutamic acid/tyrosine incubated for 25 mins by spectrometery	[PMID: 30878832]
SK-BR-3	IC₅₀	0.95 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth	[PMID: 17942920]
T47D	IC₅₀	2.4 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth Antiproliferative activity against human T47D cells assessed as inhibition of cell growth	[PMID: 17942920]
UACC-812	IC₅₀	1.9 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human UACC-812 cells assessed as inhibition of cell growth Antiproliferative activity against human UACC-812 cells assessed as inhibition of cell growth	[PMID: 17942920]
ZR-75-1	IC₅₀	>10 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human ZR-75-1 cells assessed as inhibition of cell growth Antiproliferative activity against human ZR-75-1 cells assessed as inhibition of cell growth	[PMID: 17942920]
ZR-75-30	IC₅₀	1.5 μM Compound: Chemical Probe: CP-724,714	Antiproliferative activity against human ZR-75-30 cells assessed as inhibition of cell growth Antiproliferative activity against human ZR-75-30 cells assessed as inhibition of cell growth	[PMID: 17942920]

In Vitro

CP-724714 (10-40 µM) succinate shows no significant effect on the viability of Vero cells and IPI-21 cells, and dose-dependently inhibits SADS-CoV infection^[1].

CP-724714 (20-30 µM; 12 h) succinate exhibits anti-SADS-CoV activity targeting the viral infection replication stage in IPI-21 cells and reduces HER2, Raf, and Erk phosphorylation^[1].
CP-724714 (12 h) succinate exhibits broad-spectrum anti-porcine diarrheal coronavirus (SADS-CoV, PEDV, PDCoV, and TGEV) activity in Vero cells and ST cells, with IC₅₀ values of 0.91, 2.13, 0.84, and 2.53 μM, respectively^[1].
CP-724714 (up to 10 µM; 2 h) succinate potently inhibits EGF-induced EGFR/erbB2 chimera autophosphorylation in NIH 3T3 transfected cells with an IC₅₀ of 32 nM, while showing minimal effect on EGFR autophosphorylation in EGFR-transfected NIH 3T3 cells^[2].
CP-724,714 (0.03-3 μM; 6 days) succinate reduces colony formation in erbB2-overexpressing human breast cancer cells BT-474 and SKBR3^[2].
CP-724714 (1 μM; 24 h) succinate induces G₁ phase cell cycle arrest and reduces S phase cells in human breast cancer BT-474 cells^[2].
CP-724714 (24 h) succinate exerts a direct cytotoxic effect that decreases mitochondrial membrane potential in human primary hepatocytes^[3].

CP-724714 succinate potently inhibits recombinant erbB2 kinase with an IC₅₀ of 10 nM^[2].
CP-724714 (1.2-100 µM; 7 min) succinate inhibits BSEP-mediated taurocholate (TC) transport in membrane vesicles expressing human BSEP, with an IC₅₀ of 16 µM^[3].
CP-724714 (2 µM; up to 120 min) succinate is rapidly taken up and excreted into the canaliculi in sandwich-cultured human hepatocytes^[3].
CP-724714 (0.01-100 µM; 5 min) succinate concentration-dependently inhibits OATP1B1-mediated substrate uptake in OATP1B1-transfected HEK 293 cells with an IC₅₀ of 1.7 µM^[3].
CP-724714 (0.3-100 µM) succinate inhibits MDR1-mediated efflux transport of substrate in MDR1-transfected MDCK cells with an IC₅₀ of approximately 28 µM^[3].
CP-724714 (10-100 µM; 15 min) succinate concentration-dependently inhibits CLF (IC₅₀ approximately 5 µM) and TC efflux into canaliculi in sandwich-cultured fresh and cryopreserved human hepatocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:

BT-474 cells
Concentration:

1 µM
Incubation Time:

24 h
Result:

Caused an accumulation of cells in the G1 phase and a marked reduction of cells in the S-phase.

Cell Proliferation Assay^[2]

Cell Line:

BT-474 cells and SKBR3 cells
Concentration:

0.03, 0.3, 1, 3 µM
Incubation Time:

6 days
Result:

Reduced colony formation by >80% leading to cell death.

In Vivo

CP-724714 (3.125-100 mg/kg; p.o.; single administration; 1 h) succinate dose-dependently decreases erbB2 receptor phosphorylation in athymic female mouse models bearing FRE-erbB2 xenografts^[2].
CP-724714 (25 mg/kg; p.o.; single administration; 0.5-8 h) succinate is rapidly absorbed and leads to decreased phosphorylation of the tumor erbB2 receptor in athymic female mouse models bearing FRE-erbB2 xenografts^[2].
CP-724714 (6.25-100 mg/kg; p.o.; once daily; for 8 consecutive days) succinate exhibits activity in inhibiting xenograft growth in athymic female mouse models bearing FRE-erbB2 xenografts^[2].

CP-724714 (1-100 mg/kg; p.o.; twice daily; 40 days) succinate exhibits dose-dependent inhibition of tumor growth and causes tumor regression at high doses in athymic female mouse models bearing human breast cancer BT-474 xenografts^[2].
CP-724714 (25-100 mg/kg; p.o.; twice daily; 48 days) succinate significantly inhibits tumor growth in athymic female mouse models bearing human breast cancer MDA-MB-453 xenografts^[2].

CP-724714 (30-100 mg/kg; p.o.; single administration; 0.5 h) succinate significantly decreases the levels of activated Erk and Akt phosphorylation in tumors in athymic female mouse models bearing BT-474 xenografts^[2].
CP-724714 (30-100 mg/kg; p.o.; single administration; 0.5-8 h) succinate induces time- and dose-dependent tumor cell apoptosis and increases cleaved caspase-3 release in athymic female mouse models bearing FRE-erbB2 xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD-1 nu/nu (female, ~20 g, FRE-erbB2 fibroblast xenograft model)^[2]
Dosage:

3.125, 6.25, 12.5, 25, 30, 50, 100 mg/kg
Administration:

p.o.; single dose or once daily; processed from 0.5 to 8 hours for pharmacodynamic evaluation, or dosed for 8 consecutive days for tumor growth
Result:

Reduced the phosphorylation of erbB2 receptors in the tumors.
Induced apoptosis of tumor cells and increased the immunostaining for cleaved caspase-3.
Inhibited the growth of FRE-erbB2 xenografts in a dose-dependent manner.

Animal Model:

CD-1 nu/nu (female, ~20 g, BT-474 or MDA-MB-231 human breast carcinoma xenograft model)^[2]
Dosage:

1, 10, 25, 30, 50, 100 mg/kg
Administration:

p.o.; twice daily or single dose; dosed for up to 40 or 48 consecutive days, or evaluated at 0.5 hours for signaling
Result:

Inhibited the growth of human breast carcinoma xenografts (BT-474 and MDA-MB-453) dose-dependently, leading to tumor regression at the highest dose in the BT-474 model.
Markedly reduced the levels of phosphorylated Erk and phosphorylated Akt in BT-474 xenografts within 0.5 hours of administration.

Related Protocols :

Chemical Information

CAS. Nr. 383432-38-0
Appearance Solid
Molecular Weight 469.55
Formel C₂₇H₂₇N₅O₃
Color Light yellow to yellow
SMILES

O=C(COC)NC/C=C/C1=CC2=C(N=CN=C2C=C1)NC3=CC=C(C(C)=C3)OC4=CC=C(N=C4)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Cell Host Microbe

Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. [Abstract]

2024 Aug 14;32(8):1365-1379.e10. PMID: 39059397
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Virol Sin

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]

2023 Oct;38(5):778-786. PMID: 37406816

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (106.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1297 mL

10.6485 mL

21.2970 mL

5 mM

0.4259 mL

2.1297 mL

4.2594 mL

10 mM

0.2130 mL

1.0648 mL

2.1297 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhou L, et al. Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. Virologica Sinica. 2023 Oct;38(5):778-786. [Content Brief]

[2]. Jani JP, et al. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer research. 2007 Oct 15;67(20):9887-93. [Content Brief]

[3]. Feng B, et al. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicological sciences : an official journal of the Society of Toxicology. 2009 Apr;108(2):492-500. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1297 mL	10.6485 mL	21.2970 mL	53.2425 mL
	5 mM	0.4259 mL	2.1297 mL	4.2594 mL	10.6485 mL
	10 mM	0.2130 mL	1.0648 mL	2.1297 mL	5.3242 mL
	15 mM	0.1420 mL	0.7099 mL	1.4198 mL	3.5495 mL
	20 mM	0.1065 mL	0.5324 mL	1.0648 mL	2.6621 mL
	25 mM	0.0852 mL	0.4259 mL	0.8519 mL	2.1297 mL
	30 mM	0.0710 mL	0.3549 mL	0.7099 mL	1.7747 mL
	40 mM	0.0532 mL	0.2662 mL	0.5324 mL	1.3311 mL
	50 mM	0.0426 mL	0.2130 mL	0.4259 mL	1.0648 mL
	60 mM	0.0355 mL	0.1775 mL	0.3549 mL	0.8874 mL
	80 mM	0.0266 mL	0.1331 mL	0.2662 mL	0.6655 mL
	100 mM	0.0213 mL	0.1065 mL	0.2130 mL	0.5324 mL

Bioz

CP-724714

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CP-724714

Publications Citing Use of MedChemExpress (MCE) CP-724714

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle Raf Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen